Citius Pharmaceuticals Inc vs iShares Core High Dividend ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while iShares Core High Dividend ETF trades at $29.09. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | HDV | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | — |
52-Week High | $1.82 | $29.14 |
52-Week Low | $0.48 | $23.64 |
Enterprise Value | $16.23M | — |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
HDV trades at $29.04, up 0.17% with a bullish technical signal from moving averages. The ETF focuses on high-quality dividend stocks, delivering a 3.1% yield while outperforming the S&P 500 by 9 percentage points year-to-date. Recent institutional buying includes Bay Colony Advisors increasing holdings by 370.7% and 180 Wealth Advisors by 386.2% in Q2 2026. Technical indicators show strong momentum with RSI at 76.33 suggesting overbought conditions, while support and resistance cluster around $29.
HDV offers attractive income generation through quality dividend stocks, with defensive sector exposure providing stability. The ETF's screening methodology favors companies with sustainable dividends and strong balance sheets. Key risks include interest rate sensitivity and sector concentration in healthcare and energy. Current technical overbought conditions may limit near-term upside potential despite strong institutional interest.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →